Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism

Thrombosis Research

Volumn 135, Issue 2, 2015, Pages 388-393

  Arachchillage, D R J ^a   Efthymiou, M ^a   Mackie, I J ^a   Lawrie, A S ^a   Machin, S J ^a   Cohena, H ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

D dimer; Prothrombin fragment 1.2; Rivaroxaban; Thrombin generation; Thrombin antithrombin complex; Warfarin

Indexed keywords

D DIMER; RIVAROXABAN; THROMBIN ANTITHROMBIN COMPLEX; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING PARAMETERS; COAGULATION ACTIVATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; IN VIVO STUDY; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING; DRUG EFFECTS; MIDDLE AGED; PROCEDURES;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR XA INHIBITORS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MORPHOLINES; THIOPHENES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84921493869     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.11.037     Document Type: Article

References (37)

1. Xarelto 20mg film-coated tablets. Summary of Product Characteristics last updated on the eMC: 06/01/2014. 6-1-2014. Ref Type: Online Source
2. Besser M, Baglin C, Luddington R, van H V, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008;6:1720-5.
3. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 2008;54:2042-8.
4. Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987;80:1535-44.
5. Tripodi A, Cattaneo M, Molteni A, Cesana BM, Mannucci PM. Changes of prothrombin fragment 1 + 2 (F 1 + 2) as a function of increasing intensity of oral anticoagulation-considerations on the suitability of F 1 + 2 to monitor oral anticoagulant treatment. Thromb Haemost 1998;79:571-3.
6. Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1 + 2 levels. Blood 1992;79:2034-8.
7. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355:1780-9.
8. Poli D, Antonucci E, Ciuti G, Abbate R, Prisco D. Combination of D-dimer, F1 + 2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. J Thromb Haemost 2008;6:708-10.
9. Poli D, Grifoni E, Antonucci E, Arcangeli C, Prisco D, Abbate R, et al. Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. J Thromb Thrombolysis 2010;30:294-9.
10. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
11. Samama MM, Contant G, Spiro TE, Perzborn E, Le FL, Guinet C, et al. Laboratory assessment of rivaroxaban: a review. Thromb J 2013;11:11.
12. Green L, Lawrie AS, Patel S, Hossain F, Chitolie A, Mackie IJ, et al. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol 2010;151:469-76.
13. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-7.
14. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
15. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737-40.
18. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47-58.
19. Hemker HC, Giesen P, Al DR, Regnault V, de SE, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15.
20. Lawrie AS, Hills JF, Longair IF, Green LF, Gardiner CF, Machin SJ FAU, Cohen H. The clinical significance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients.
21. Gatt A, van Veen JJ FAU - Bowyer, Bowyer AF, Woolley AM FAU, Cooper PF, Kitchen S FAU - Makris, Makris M. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation.
22. Spronk HM, Dielis AW FAU - Panova-Noeva M, Panova-Noeva MF, van Oerle RF, Govers-Riemslag JW FAU - Hamulyak K, Hamulyak KF, Falanga AF, Cate HT. Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?
23. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453-61.
24. Samama MM, Mendell J, Guinet C, Le FL, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 2012;129:e77-82.
25. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
26. Bloemen S, Hemker HC, Al DR. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica 2013;98:549-54.
27. Jesty J, Lorenz A, Rodriguez J, Wun TC. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood 1996;87:2301-7.
28. Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2014;111:989-95.
29. Bostrom SL, Hansson GF, Sarich TC, Wolzt M. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. Thromb Res 2004;113:85-91.
30. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000;84:747-51.
31. Brodin E, Seljeflot I, Arnesen H, Hurlen M, Appelbom H, Hansen JB. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res 2009;123:573-9.
32. Gerotziafas GT, Dupont C, Spyropoulos AC, Hatmi M, Samama MM, Kiskinis D, et al. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. Thromb Haemost 2009;102:42-8.
33. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013;109:127-36.
34. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombinantithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988;59:101-6.
35. Greenberg CS, Hursting MJ, Macik BG, Ortel TL, Kane WH, Moore BM. Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. Clin Chem 1994;40:1962-9.
36. Hager K, Platt D. Fibrin degeneration product concentrations (D-dimers) in the course of ageing. Gerontology 1995;41:159-65.
37. Al DR, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002;88:576-82.